1. Home
  2. NKSH vs IPHA Comparison

NKSH vs IPHA Comparison

Compare NKSH & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo National Bankshares Inc.

NKSH

National Bankshares Inc.

N/A

Current Price

$41.92

Market Cap

256.1M

Sector

Finance

ML Signal

N/A

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

N/A

Current Price

$1.63

Market Cap

165.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NKSH
IPHA
Founded
1891
1999
Country
United States
France
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
256.1M
165.3M
IPO Year
1995
2014

Fundamental Metrics

Financial Performance
Metric
NKSH
IPHA
Price
$41.92
$1.63
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $6.67
AVG Volume (30 Days)
26.1K
★ 37.8K
Earning Date
10-22-2026
09-17-2026
Dividend Yield
★ 3.60%
N/A
EPS Growth
★ 100.81
N/A
EPS
★ 1.57
N/A
Revenue
★ $8,176,000.00
N/A
Revenue This Year
N/A
$390.56
Revenue Next Year
N/A
$143.06
P/E Ratio
$26.91
★ N/A
Revenue Growth
★ 9.39
N/A
52 Week Low
$27.00
$1.18
52 Week High
$43.31
$2.71

Technical Indicators

Market Signals
Indicator
NKSH
IPHA
Relative Strength Index (RSI) 51.39 31.34
Support Level $41.41 $1.34
Resistance Level $43.04 $1.87
Average True Range (ATR) 0.85 0.11
MACD -0.14 -0.03
Stochastic Oscillator 35.26 0.00

Price Performance

Historical Comparison
NKSH
IPHA

About NKSH National Bankshares Inc.

National Bankshares Inc is a bank holding company. It focuses on lending to small and mid-sized businesses and individuals. The types of loans it offers include commercial and agricultural loans, commercial real estate, construction loans for commercial and residential properties, residential real estate, home equity, and various consumer loan products. It also operates an insurance and brokerage subsidiary. The company earns its revenue from interest and fees on loans, non-interest income, and investments.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: